Literature DB >> 34297829

Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

Maria Cristina Puzzolo1, Giulia Radice1, Nadia Peragine1, Maria Stefania de Propris1, Paola Mariglia1, Marco Vignetti1,2, Antonella Vitale1, Renato Bassan3, Mario Annunziata4, Gianluca Gaidano5, Alessandro Rambaldi6, Sabina Chiaretti1, Anna Guarini7, Robin Foà1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34297829     DOI： 10.1182/blood.2021011822

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Authors:  Mahmoud R Gaballa; Pinaki Banerjee; Denái R Milton; Xianli Jiang; Christina Ganesh; Sajad Khazal; Vandana Nandivada; Sanjida Islam; Mecit Kaplan; May Daher; Rafet Basar; Amin Alousi; Rohtesh Mehta; Gheath Alatrash; Issa Khouri; Betul Oran; David Marin; Uday Popat; Amanda Olson; Priti Tewari; Nitin Jain; Elias Jabbour; Farhad Ravandi; Hagop Kantarjian; Ken Chen; Richard Champlin; Elizabeth Shpall; Katayoun Rezvani; Partow Kebriaei
Journal:  Blood       Date:  2022-03-24       Impact factor: 22.113

2.  Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Massimiliano Bonifacio; Cristina Papayannidis; Federico Lussana; Nicola Fracchiolla; Mario Annunziata; Simona Sica; Mario Delia; Robin Foà; Giovanni Pizzolo; Sabina Chiaretti
Journal:  Front Oncol       Date:  2022-01-06       Impact factor: 6.244

3.  Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation.

Authors:  Maria Cristina Puzzolo; Massimo Breccia; Paola Mariglia; Gioia Colafigli; Sara Pepe; Emilia Scalzulli; Elena Mariggiò; Roberto Latagliata; Anna Guarini; Robin Foà
Journal:  J Clin Med       Date:  2022-09-23       Impact factor: 4.964
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.